Announcements Trials
Browse Landscape

Phase

Phase 2 78Phase 1 28Phase 3 22Phase 1/2 7Phase 4 4Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 23Withdrawn 7Completed 7Unknown 5Terminated 4Active not recruiting 4Not yet recruiting 2

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 6Tumor-Agnostic 1

Conditions

Breast Neoplasms 6Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Fulvestrant × Clear all
NCT03363893 2025-11-12

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Carrick Therapeutics Limited

Phase 1/2 Completed
124 enrolled
Tumor-Agnostic

Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed
144 enrolled 25 charts
Breast

Breast Neoplasms

NCT05054374 2025-05-23

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
6 enrolled 4 charts
Breast

Breast Neoplasms

NCT03481998 2023-11-21

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Completed
104 enrolled
Breast

Breast Neoplasms

NCT03344536 2022-11-25

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
10 enrolled 7 charts
Breast

Breast Neoplasms

NCT02657343 2022-08-01

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Dana-Farber Cancer Institute

Phase 1/2 Completed
25 enrolled 16 charts
Breast

Breast Neoplasms

NCT01202591 2016-02-11

GLOW

AstraZeneca

Phase 1/2 Completed
127 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡